Dr. Allison Ashworth, Radiation Oncologist with Study from the London Regional Cancer Program in Ontario, Canada
Stations, the following is a news announcement. Suggested lead in 3, 2, 1…
(INTRO)
More than 11,000 of the world’s top cancer doctors and scientists gathered at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO) at the Moscone Center in San Francisco. This year’s theme for the four-day event, September 14-17, was “Targeting Cancer: Technology & Biology” and highlighted how technology and biology advance the field and improve patient outcomes and quality of life.
Dr. Allison Ashworth, a radiation oncologist discusses a study at the London Regional Cancer Program in Ontario, Canada, on the effects of radiation therapy on patients with advanced stages of lung cancer.
(ASHWORTH)
GENERALLY SPEAKING THIS TYPE OF CANCER, STAGE FOUR, IS TREATED PALLIATIVELY, FOR SYMPTOM CONTROL AND MOST PATIENTS LIVE ONLY A FEW MONTHS. BUT, THERE IS SOME EVIDENCE TO SUGGEST SOME PATIENTS WITH ONLY A LIMITED NUMBER OF METASTATIC SITES MAY BENEFIT FROM AGGRESSIVE TREATMENT, AGGRESSIVE MEANING SURGERY OR HIGH DOSE FOCUSED RADIATION CALLED STEREOTACTIC RADIATION. THE PATIENTS WHO DID THE BEST WERE PATIENTS WHO TENDED TO DEVELOP THEIR METASTASIS SOME PERIOD AFTER THEY WERE INITIALLY DIAGNOSED WITH LUNG CANCER THAT WAS INITIALLY THOUGHT TO BE CURATIVE.
(CLOSE)
For more information, visit www.astro.org.